Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Accenture
Merck
Cantor Fitzgerald
Mallinckrodt
Colorcon
Moodys
US Army

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,241,946

« Back to Dashboard

Which drugs does patent 9,241,946 protect, and when does it expire?

Patent 9,241,946 protects ORACEA and is included in one NDA.

This patent has seventeen patent family members in twelve countries.
Summary for Patent: 9,241,946
Title:Methods of treating acne
Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
Inventor(s): Ashley; Robert A. (Newtown, PA)
Assignee: GALDERMA LABORATORIES INC. (Fort Worth, TX)
Application Number:14/753,544
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,241,946
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,241,946

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp ORACEA doxycycline CAPSULE;ORAL 050805-001 May 26, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,241,946

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,232,572 Methods of treating rosacea ➤ Sign Up
7,014,858 Use methods of treating acne and telangiectasia ➤ Sign Up
8,658,189 Methods of treating acne ➤ Sign Up
8,603,506 Methods of treating acne ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Citi
Medtronic
Federal Trade Commission
US Department of Justice
Fish and Richardson
Cipla
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.